Abstract: Triple-helical peptide inhibitors (THPIs) of matrix metalloproteinases (MMPs) have recently been demonstrated to be effective in a variety of animal models of disease, coincidental with knockout studies. However, passenger mutations have been described in MMP knockout mice that impact the activity of other proteins, including caspase-11. Thus, it is possible that the results observed with THPIs may be based on inhibition of caspase-11, not MMPs. The present study evaluated whether THPIs were cross-reactive with caspase-11. Two different THPIs were tested, one that is known to inhibit MMP-1 and MMP-8 (GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI) and one that is selective for MMP-2 and MMP-9 (α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14,32 ,Flp 15,33 ] THPI). No inhibition of caspase-11 was observed with GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI, even at an inhibitor concentration of 5 µM, while 5 µM α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 , Flp 15, 33 ] THPI exhibited 40% inhibition of caspase-11. Further testing of GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI revealed nM inhibition of MMP-2, MMP-9, and MMP-13. Thus, the effectiveness of GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI observed in a sepsis animal model may not be due to caspase-11 inhibition, but may be due to broader MMP inhibition than previously thought.
Introduction
The matrix metalloproteinase (MMP) family of enzymes has been implicated in a great variety of diseases [1] [2] [3] [4] [5] [6] , resulting in the pursuit of MMP inhibitors that has spanned decades [1, [7] [8] [9] [10] [11] [12] . A variety of phosphorus-based peptides have been developed as MMP inhibitors [7, 13, 14] . Phosphinates/phosphinic peptides contain a hydrolytically stable, tetrahedral phosphinic pseudo-dipeptide moiety which mimics the tetrahedral intermediate formed during Zn 2+ metalloproteinase-catalyzed amide bond hydrolysis. We have reported that phosphinic triple-helical peptides (THPs) behave as effective transition state analog inhibitors of collagenolytic MMPs [15] [16] [17] [18] [19] . Recently, the triple-helical peptide inhibitor (THPI) (Gly-Pro-Hyp) 4 -Gly-mep-Flp-Gly-Pro-Gln-{GlyΨ(PO 2 H-CH 2 )Ile}-His-Lys-Gln-Arg-Gly-Val-Arg-Glymep-Flp-(Gly-Pro-Hyp) 4 -Tyr-NH 2 (designated GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI) (where mep = (2S,4R)-4-methylproline, Flp = (2S,4R)-4-fluoroproline, and Hyp = 4-hydroxy-l-proline) was shown to inhibit MMP-8 in the nanomolar range while being a much weaker inhibitor of MT1-MMP [19] . Gene ablation studies have indicated that MMP-8 facilitates sepsis in animal models, while MT1-MMP is protective [19] [20] [21] . GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI was thus applied in an animal model of sepsis [19] . Using the cecal ligation and puncture (CLP) sepsis model, 70% of the wild-type mice treated with GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI survived after 7 days, while none of the non-treated wild-type mice did [19] .
Genetically modified (knockout) mice have been utilized to delineate the roles of MMPs in normal physiological function and pathological states. To examine the specificity of the GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI, Mmp8 null mice underwent CLP and were then either treated with the THPI or not treated. A survival advantage during sepsis was observed for Mmp8 null mice compared with wild-type mice [19] . Survival of THPI-treated wild-type mice mirrored that of non-treated Mmp8 null mice, while survival of Mmp8 null mice was not augmented by inhibitor treatment [19] . Thus, in consideration of the Mmp8 null mice data, the GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI was deemed as acting specifically towards MMP-8 in vivo.
The identification of passenger mutations that can accompany MMP knockouts has raised serious concerns as to the interpretation of results from disease models in which MMPs were implicated [22] . For example, Mmp7, Mmp8, or Mmp13 null mice were found to be protected from lipopolysaccharide (LPS) lethality (septic shock) [23] [24] [25] . However, these knockout mice carried a passenger mutation that inactivated Casp11 (the mouse ortholog of human Casp4 and Casp5) [22] . Caspase-11 has been demonstrated to participate in LPS-induced endotoxic shock and subsequent lethality [26, 27] . Mice possessing a non-functional caspase-11 are more resistant to LPS-induced septic shock [28] , and the passenger mutation of Casp11 resulted in mice resistant to LPS-induced endotoxic shock [22, 29] .
In the above example, the results from MMP-8 knockout mice appear to be validated through the use of a THPI which targeted the MMP of interest (MMP-8) in wild-type mice, as the same phenotype was observed for the CLP knockout mice and the CLP wild type mice treated with the GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI. However, if the applied THPI non-specifically inhibited other enzymes, interpretation of the results becomes ambiguous. Given that the Mmp8 null mice may have had a Casp11 inactivating mutation [22] , the mirroring of survival in the Mmp8 null mice by the inhibitor treated wild-type mice could have been the result of the THPI inhibiting caspase-11 in the wild-type mice. MMP inhibitors are not anticipated to inhibit caspase-11, due to the different active site chemistries and sequence specificities [30] [31] [32] [33] [34] . However, recent research has indicated that caspase-11 recognition of substrates can be strongly influenced by motifs outside of the active site [34] , and thus, there is a possibility of non-specific inhibition by MMP inhibitors whose structures may be complimentary to caspase-11 motifs. In addition, MMP inhibitors that are designed to interact with the active site Zn 2+ can inhibit non-MMP activity by non-selective metal binding [35, 36] . The present study has examined the inhibition of (a) caspase-11 by two phosphinate-based THPIs and (b) other collagenolytic MMPs by GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI.
Results
Caspase-11 hydrolysis of acetyl-Trp-Glu-His-Asp-pNA was examined at several enzyme and substrate concentrations to obtain conditions under which enzyme inhibition could be studied. It was ultimately determined that 3 U/µL (1.08 µM) caspase-11 and 250 µM acetyl-Trp-Glu-His-Asp-pNA provided a reasonably linear rate of hydrolysis over 15 min. Acetyl-Leu-Glu-Val-Asp-CHO was incubated with caspase-11 at a concentration of 5 µM for 2 h prior to the addition of substrate, and was found to completely inhibit enzymatic activity (Figure 1) .
The potential inhibition of caspase-11 by GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI was examined by adding 5 µM of the inhibitor to the enzyme for 2 h prior to addition of substrate. A 2 h incubation was utilized based on (a) the generally observed behavior of slow on and off rates for tight-binding inhibitors [37] , (b) studies demonstrating that high affinity phosphinate inhibitors of Zn 2+ metalloproteinases are slow binding [38] , and (c) our prior studies using THPIs [39] . This concentration was comparable to that used in our prior CLP mouse model studies (13.5 µM) [19] . No inhibition of caspase-11 activity was observed over 15 min (Figure 1 ). GlyΨ{PO2H-CH2}Ile-His-Lys-Gln THPI (purple). Acetyl-Trp-Glu-His-Asp-pNA alone (green) was used as a control.
A second THPI was examined for inhibitory potential towards caspase-11. (Gly-Pro-Hyp)4-Gly-
is an effective, and selective, inhibitor of MMP-2 and MMP-9, with Ki values of 2.24 and 0.98 nM at 37 °C for MMP-2 and MMP-9, respectively, and exhibiting no or weak (Ki = 10-50 μM) inhibition of MMP-1, MMP-3, MMP-8, MMP-13, and MT1-MMP [15, 19] . α1(V)GlyΨ{PO2H-CH2}Val [mep14,32,Flp15,33] THPI was recently shown to be efficacious in an animal model of multiple sclerosis [19] . 5 μM of α1(V)GlyΨ{PO2H-CH2}Val [mep14,32,Flp15,33] THPI was added to the enzyme for 2 h prior to addition of substrate. Approximately 40% inhibition of caspase-11 activity was observed after 15 min ( Figure  2 ). The extent of this inhibition did not increase after 1 h (data not shown). We examined the inhibition of caspase-11 by the α1(V)GlyΨ{PO2H-CH2}Val [mep14,32,Flp15,33] THPI using no inhibitor preincubation time, and found no inhibition to occur at early time points (data not shown), in similar fashion to what was observed for a 2 h inhibitor pre-incubation ( Figure 2 ). A second THPI was examined for inhibitory potential towards caspase-11.
(Gly-Pro-Hyp) 4 14, 32 ,Flp 15, 33 ] THPI) is an effective, and selective, inhibitor of MMP-2 and MMP-9, with K i values of 2.24 and 0.98 nM at 37 • C for MMP-2 and MMP-9, respectively, and exhibiting no or weak (K i = 10-50 µM) inhibition of MMP-1, MMP-3, MMP-8, MMP-13, and MT1-MMP [15, 19] . α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 ,Flp 15, 33 ] THPI was recently shown to be efficacious in an animal model of multiple sclerosis [19] . 5 µM of α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 ,Flp 15, 33 ] THPI was added to the enzyme for 2 h prior to addition of substrate. Approximately 40% inhibition of caspase-11 activity was observed after 15 min (Figure 2 ). The extent of this inhibition did not increase after 1 h (data not shown). We examined the inhibition of caspase-11 by the α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 ,Flp 15, 33 ] THPI using no inhibitor pre-incubation time, and found no inhibition to occur at early time points (data not shown), in similar fashion to what was observed for a 2 h inhibitor pre-incubation ( Figure 2 ). GlyΨ{PO2H-CH2}Ile-His-Lys-Gln THPI (purple). Acetyl-Trp-Glu-His-Asp-pNA alone (green) was used as a control.
A second THPI was examined for inhibitory potential towards caspase-11. (Gly-Pro-Hyp)4-Glymep-Flp-Gly-Pro-Pro-GlyΨ{PO2H-CH2}Val-Val-Gly-Glu-Gln-Gly-Glu-Gln-Gly-Pro-Pro-Gly-mepFlp-(Gly-Pro-Hyp)4-NH2 (designated α1(V)GlyΨ{PO2H-CH2}Val [mep14,32,Flp15,33] THPI) is an effective, and selective, inhibitor of MMP-2 and MMP-9, with Ki values of 2.24 and 0.98 nM at 37 °C for MMP-2 and MMP-9, respectively, and exhibiting no or weak (Ki = 10-50 μM) inhibition of MMP-1, MMP-3, MMP-8, MMP-13, and MT1-MMP [15, 19] . α1(V)GlyΨ{PO2H-CH2}Val [mep14,32,Flp15,33] THPI was recently shown to be efficacious in an animal model of multiple sclerosis [19] . 5 μM of α1(V)GlyΨ{PO2H-CH2}Val [mep14,32,Flp15,33] THPI was added to the enzyme for 2 h prior to addition of substrate. Approximately 40% inhibition of caspase-11 activity was observed after 15 min ( Figure  2 ). The extent of this inhibition did not increase after 1 h (data not shown). We examined the inhibition of caspase-11 by the α1(V)GlyΨ{PO2H-CH2}Val [mep14,32,Flp15,33] THPI using no inhibitor preincubation time, and found no inhibition to occur at early time points (data not shown), in similar fashion to what was observed for a 2 h inhibitor pre-incubation (Figure 2) . The inhibitory potency of GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI was initially examined for MMP-1, MMP-3, MMP-8, and MT1-MMP (Table 1) [19] . Selectivity within the collagenolytic MMPs was further examined by treating MMP-2, MMP-9, and MMP-13 with GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI. All three enzymes were inhibited by the THPI (Table 1) . The K i value for MMP-13 was better than that observed for MMP-8 (Table 1) . MMP-2 and MMP-9 were very efficiently inhibited by GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI, with K i values below 10 nM (Table 1) . 
Discussion
The Mmp8 null mice utilized in our CLP study were on a C57BL/6J background [19] , which may still harbor the Casp11 mutation depending upon the extent of backcrossing [22] . The inhibition of caspase-11 by a THPI could occur by two non-exclusive mechanisms: (a) chelation of a caspase-11 metal ion by the THPI phosphinate; and (b) binding of the THPI sequence to a complementary motif on the surface of caspase-11. To consider possibility (a), the mechanism by which caspase-11 contributes to CLP/LPS-induced lethality needs to be taken into account. The CLP sepsis model induces polymicrobial peritonitis and results in translocation of bacteria into the bloodstream (bacteremia) [40, 41] . Both Gram negative and Gram positive bacteria enter the bloodstream and tissues, with a shift to Gram negative bacteria with disease progression [40] . Gram negative, but not Gram positive, bacteria activate the caspase-11 non-canonical inflammasome pathway [28] . Caspase-11 directly binds the lipid A tail of LPS via the caspase recruitment domain motif [28] . LPS binding first results in the formation of caspase-11 dimers, followed by auto-hydrolysis at the interdomain linker residue Asp285 [42] . Caspase-11 then undergoes oligomerization, ultimately inducing pyroptosis and secretion of the pro-inflammatory cytokines interleukin-1β and interleukin-18 [28] .
MMP inhibitors have an unfortunate history of non-selectivity. Of specific concern is the ability of zinc binding groups to behave in a non-selective fashion. For example, hydroxamic acids have been commonly used in MMP inhibitors, but the ability of hydroxamic acids to non-specifically chelate metal ions, in some cases with greater affinity than zinc, has been noted [35, 36] . Caspase-11 is a Cys protease, and it is not anticipated that non-selective metal chelation would be a concern as caspase family members caspase-1, caspase-2, caspase-3, caspase-7, caspase-8, and caspase-9 do not possess structural metals [43, 44] . However, the human orthologs of caspase-11, caspase-4 and caspase-5, have been reported to each have one Mg 2+ ion present (https://swissmodel.expasy.org/repository/uniprot/P49662 and https://swissmodel.expasy.org/repository/uniprot/P51878). Homology modeling indicated that in caspase-4 the Mg 2+ binds to His338 of the A chain, His338 of the B chain, and Tyr370 of the B chain, while in caspase-5, the Mg 2+ binds to His395 of the A chain and Glu398 of the B chain. Thus, the Mg 2+ ion could stabilize caspase-11 dimers, and dimerization is an important step in the caspase-11 pathway contributing to endotoxic shock (see above). As indicated by studies with nucleic acids, phosphates will readily bind Mg 2+ [45, 46] . The GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI did not show inhibition of caspase-11, and thus, Mg 2+ ions most likely do not undergo non-specific chelation by THPIs (see above).
In consideration of mechanism (b), THPIs have extended sequences that interact with regions well outside of the active site in MMPs [16, 17] . These regions of interaction are referred to as secondary binding sites (exosites). The THPI extended sequences could interact with caspase-11 exosites. It has been proposed that caspase-11 substrate specificity is governed by exosite interactions, as the substrate preferences of caspase-11 cannot be explained by the sequences at the active site [34] . One possibility is that negatively charged residues in the P 7 -P 10 region may be unfavorable for substrate interaction with caspase-11 [34] . GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI possesses no negative charges, and thus could interact with caspase-11. However, as this THPI did not inhibit caspase-11, we can assume that there is no exosite interaction.
It is interesting to note that α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 ,Flp 15, 33 ] THPI exhibited some inhibition of caspase-11 activity, although it occurred at a relatively high inhibitor concentration (5 µM). It is not likely that this inhibition was due to Mg 2+ chelation (based on the lack of caspase-11 inhibition by GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI). This suggests a possible interaction between α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 ,Flp 15, 33 ] THPI and a caspase-11 allosteric site, although α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 ,Flp 15, 33 ] THPI possesses 6 negatively charged residues, which are not favored in the P 7 -P 10 region by caspase-11 (see above).
There are two caveats to the interpretation of results from the present study. First, the caspase-11 substrate used here is small (4 amino acids), whereas in the CLP/LPS animal models caspase-11 is processing proteins. An exosite-binding inhibitor might not impact caspase-11 hydrolysis of a small substrate but could impact processing of a protein, unless binding to the exosite had an allosteric effect on the enzyme. Second, chelation of Mg 2+ ions might not impact caspase-11 activity towards a small substrate, but rather inhibit dimerization of the enzyme. Dimerization might be required to facilitate specific proteolytic activities in CLP/LPS models (see above).
We presently observed that GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI did not inhibit caspase-11 activity. This result supports our prior report on the modulation of sepsis by MMP-8 inhibition, not caspase-11 inhibition [19] . However, our prior studies did not examine the full range of collagenolytic MMPs that might have been inhibited by GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI. We found that MMP-2, MMP-9, and MMP-13 are effectively inhibited by the THPI, along with MMP-8. Thus, the observed protection from sepsis in the CLP mouse model by GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI may have been due to inhibition of multiple MMPs. The use of more selective inhibitors will elucidate the role of each MMP in sepsis.
Materials and Methods
GlyΨ{PO 2 H-CH 2 }Ile-His-Lys-Gln THPI and α1(V)GlyΨ{PO 2 H-CH 2 }Val [mep 14, 32 ,Flp 15, 33 ] THPI were synthesized and characterized as described previously [19] . Recombinant caspase-11 (residues 81-373), caspase substrate acetyl-Trp-Glu-His-Asp-pNA (where pNA = p-nitroaniline) (MW 747.8 Da), and caspase-4 and caspase-5 inhibitor acetyl-Leu-Glu-Val-Asp-CHO (MW 500.6 Da) were obtained from Enzo Life Sciences, Inc.
Caspase Enzyme Assay
Caspase-11 (9 U/µL in 10 µL caspase activity buffer (100 mM 2-(N-morpholino)ethanesulfonic acid (MES)), pH 6.5, 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 10% poly(ethylene-glycol) (PEG)-8000, 10 mM dithiothreitol (DTT)) was added to 10 µL of caspase-11 inhibitor (5 µM), THPI (5 µM), or no inhibitor in caspase activity buffer. For testing THPIs as inhibitors, enzyme was incubated with THPIs for 2 h at 37 • C. Residual enzyme activity was monitored by adding 10 µL of caspase substrate in caspase activity buffer to produce a final concentration of <0.1K M . pNA cleavage from the peptide was monitored at 37 • C over 1 h using λ = 405 nm on a Bio-Tek Synergy H1 Reader or H4 Hybrid Reader.
Matrix Metalloproteinases (MMPs)
Human recombinant, full-length proMMP-8 and proMMP-13 were purchased from R&D Systems (Minneapolis, MN, USA) and activated according to the manufacturer's instructions prior to use. p-Aminophenylmercuric acetate was purchased from EMD Biosciences (San Diego, CA, USA), and trypsin (TPCK-treated) was purchased from Worthington Biochemical Corporation (Lakewood, NJ, USA). Recombinant MMP-2 and MMP-9 catalytic domain were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used directly without further activation in the desired concentration.
ProMMP-8 and proMMP-13 were activated by mixing an equal volume of stock enzyme solution and activator (p-aminomercuric acetate to a final concentration of 1 mm) followed by 2-3 h incubation in a 37 • C water bath. Activated MMPs were diluted to 200-400 nm in ice cold TSB*Zn (50 mm Tris, 100 mm NaCl, 10 mm CaCl 2 , 0.05% Brij-35, 0.02% NaN 3 , 1 µm ZnCl 2 , pH 7.5) to prevent autoproteolysis. Enzyme aliquots were either kept on wet ice and used the same day or immediately frozen at −80 • C. MMP activity was initially evaluated by using the Knight substrate (Mca-Lys-Pro-Leu-Gly-Leu-Lys-(Dnp)-Ala-Arg-NH 2 , where Mca = 7-methoxycoumarin-4-acetyl and Dnp = 2,4-dinitrophenyl) and compared with prior data [16, 17] . In this way, activity towards the substrate was used as an indicator of enzyme integrity, rather than TIMP titration, as performed previously [47] .
Inhibition Kinetic Studies
Peptide substrate and THPI solutions were prepared using TSB*Zn. 1-10 nM enzyme was incubated with varying concentration of inhibitor for 2 h at 37 • C. Residual enzyme activity was monitored by adding Knight substrate solution in TSB*Zn to produce a final concentration of <0.1K M . Initial velocity rates were determined from the first 10 min of hydrolysis when product release is linear with time. Fluorescence was measured on a Bio-Tek Synergy H1 Reader or H4 Hybrid Reader using λ excitation = 324 nm and λ emission = 393 nm. Apparent K i values were calculated from the following formulas [15] : v i /v o = {E t -I t -K i (app) + ((E t -I t -K i (app) ) 2 + 4E t K i (app) ) 0.5 }/2E t (1)
where I t is the total inhibitor concentration, E t is the total enzyme concentration, A t is the total substrate concentration, v o is the activity in the absence of inhibitor, and K M is the Michaelis constant. In our assays the value of E t /K i (app) does not exceed 100 so that the inhibitor is distributed in both free and bound forms, and K i (app) can be calculated by fitting inhibition data to equation 
